A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies

Trial Profile

A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2008

At a glance

  • Drugs Bavituximab; Carboplatin; Docetaxel; Gemcitabine; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 09 Sep 2008 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2008 Results presented at the Annual Meeting of the American Society of Clinical Oncology 2008 (abstract no. 3038), according to a Peregrine Pharmaceuticals media release (9089579).
    • 23 Mar 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top